Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prenetics Group ( (PRE) ) has issued an announcement.
On March 6, 2026, Prenetics announced that its board authorized a 12‑month share repurchase program of up to $40 million in Class A ordinary shares, underscoring management’s belief that the stock is undervalued. The move follows about $2.75 million of recent open‑market share purchases by executives, including CEO Danny Yeung, bringing total potential capital committed by insiders and the company to roughly $42.75 million.
The buyback is backed by approximately $164 million in adjusted liquidity and a zero‑debt balance sheet, supported by 2025–early 2026 divestitures that refocused the business on IM8. Management highlights IM8’s strong unit economics, 2026 revenue targets of $180–$200 million, and a stated path to adjusted EBITDA profitability by the fourth quarter of 2027, positioning the repurchase as a disciplined capital allocation decision aimed at enhancing shareholder value.
Under the program, Prenetics may repurchase shares via open market, block, or privately negotiated transactions, including through Rule 10b5‑1 trading plans, and retains discretion to modify, suspend, or discontinue the initiative. At current valuations cited by the company, its enterprise value implies a low revenue multiple for IM8, suggesting meaningful upside if execution on growth and profitability targets aligns with investor expectations.
The most recent analyst rating on (PRE) stock is a Hold with a $19.50 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
Spark’s Take on PRE Stock
According to Spark, TipRanks’ AI Analyst, PRE is a Neutral.
The score is primarily held back by weak financial performance (persistent losses and ongoing cash burn), despite improving revenue and gross margins and a currently strong balance sheet. The latest earnings call boosts the outlook with ambitious growth/margin guidance and strong liquidity, but near-term profitability remains negative and execution/concentration risks are material. Technicals are mixed with near-term weakness, and valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on PRE stock, click here.
More about Prenetics Group
Prenetics Global Limited is a Nasdaq-listed health sciences company focused on consumer health and longevity. Its flagship brand, IM8, co-founded with David Beckham and endorsed by elite athletes, offers premium, science-backed daily nutrition products and has rapidly scaled past $100 million in annualized recurring revenue across more than 30 countries.
Positioned in the fast-growing wellness and supplements market, Prenetics has streamlined its portfolio via divestitures to concentrate capital and operations on IM8’s high-growth, high-margin profile. The company reports substantial liquidity, no debt, and targets adjusted EBITDA profitability as IM8 continues global expansion.
Average Trading Volume: 241,588
Technical Sentiment Signal: Hold
Current Market Cap: $253.6M
See more data about PRE stock on TipRanks’ Stock Analysis page.